v3.25.2
Note 21 - Non-controlling Interests
12 Months Ended
May 31, 2025
Notes to Financial Statements  
Noncontrolling Interest Disclosure [Text Block]

21.

Non-controlling interests

 

The following tables summarize the information relating to the Company’s majority-owned subsidiaries, Aphria Diamond (51%) and ColCanna S.A.S. (90%) before intercompany eliminations.

 

On  January 7, 2025, the Company dissolved its 75% ownership interest in CC Pharma Nordic ApS., and as a result, the Company no longer controls CC Pharma Nordic ApS. and thus no longer consolidates this entity.

 

On  January 16, 2025, MedMen exited receivership and substantially all of its remaining assets were transferred to a new entity owned by MedMen’s secured creditors, including SH Acquisition. In connection with this restructuring, the Company disposed of its MedMen Convertible Note in exchange for on option to acquire a 68% membership interest in SH Acquisition for $1.00 upon U.S. federal cannabis legalization. See Note 11 (Convertible notes receivable). As a result, the Company no longer controls SH Acquisition and thus no longer consolidates this entity.  

 

 

Summarized balance sheet information of the entities in which there is a non-controlling interest as of  May 31, 2025:

 

  

SH

  

CC Pharma

  

Aphria

  

ColCanna

  

May 31,

 
  

Acquisition

  

Nordic ApS

  

Diamond

  

S.A.S.

  

2025

 

Current assets

 $  $  $83,390  $20  $83,410 

Non-current assets

        114,677   3,348   118,025 

Current liabilities

        (126,986)  (6,953)  (133,939)

Non-current liabilities

        (31,720)  (1,442)  (33,162)

Net assets

 $  $  $39,361  $(5,027) $34,334 

 

Summarized balance sheet information of the entities in which there is a non-controlling interest as of  May 31, 2024:

 

  

SH

  

CC Pharma

  

Aphria

  

ColCanna

  

May 31,

 
  

Acquisition

  

Nordic ApS

  

Diamond

  

S.A.S.

  

2024

 

Current assets

 $  $12  $95,720  $3  $95,735 

Non-current assets

  32,000      124,675   3,637   160,312 

Current liabilities

     (9)  (130,945)  (6,913)  (137,867)

Non-current liabilities

        (24,482)  (1,452)  (25,934)

Net assets

 $32,000  $3  $64,968  $(4,725) $92,246 

 

Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2025:

 

  

SH

  

CC Pharma

  

Aphria

  

ColCanna

  

May 31,

 
  

Acquisition

  

Nordic ApS

  

Diamond

  

S.A.S.

  

2025

 

Revenue

 $  $  $78,414  $  $78,414 

Total expenses

  20,000   11   54,274   290   74,575 

Net (loss) income

  (20,000)  (11)  24,140   (290)  3,839 

Other comprehensive (loss) income

     8   (45)  (12)  (49)

Net comprehensive (loss) income

 $(20,000) $(3) $24,095  $(302) $3,790 

Non-controlling interest %

  32%  25%  49%  10% 

NA

 

Comprehensive (loss) income attributable to NCI

  (6,400)  (1)  11,807   (30)  5,376 

Additional income attributable to NCI

              - 

Net comprehensive (loss) income attributable to NCI

 $(6,400) $(1) $11,807  $(30) $5,376 

 

Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2024:

 

  

SH

  

CC Pharma

  

Aphria

  

ColCanna

  

May 31,

 
  

Acquisition

  

Nordic ApS

  

Diamond

  

S.A.S.

  

2024

 

Revenue

 $  $  $103,331  $  $103,331 

Total expenses

  42,681   (1,064)  40,935   (203)  82,349 

Net (loss) income

  (42,681)  1,064   62,396   203   20,982 

Other comprehensive (loss) income

     (9)  171   (334)  (172)

Net comprehensive (loss) income

 $(42,681) $1,055  $62,567  $(131) $20,810 

Non-controlling interest %

  32%  25%  49%  10% 

NA

 

Comprehensive (loss) income attributable to NCI

  (13,658)  264   30,658   (13)  17,251 

Additional income attributable to NCI

        5,336      5,336 

Net comprehensive (loss) income attributable to NCI

 $(13,658) $264  $35,994  $(13) $22,587 

 

Summarized income statement information of the entities in which there is a non-controlling interest for the fiscal year ended May 31, 2023:

 

  

SH

  

CC Pharma

  

Aphria

  

ColCanna

  

May 31,

 
  

Acquisition

  

Nordic ApS

  

Diamond

  

S.A.S.

  

2023

 

Revenue

 $  $126  $161,453  $1  $161,580 

Total expenses

  107,297   748   85,460   57,293   250,798 

Net (loss) income

  (107,297)  (622)  75,993   (57,292)  (89,218)

Other comprehensive (loss) income

  70,778   (21)  (961)  (34,643)  35,153 

Net comprehensive (loss) income

 $(36,519) $(643) $75,032  $(91,935) $(54,065)

Non-controlling interest %

  32%  25%  49%  10% 

NA

 

Comprehensive (loss) income attributable to NCI

  (11,686)  (161)  36,766   (9,194)  15,725 

Additional income attributable to NCI

        11,421      11,421 

Net comprehensive (loss) income attributable to NCI

 $(11,686) $(161) $48,187  $(9,194) $27,146